PitchSend

Investor Presentaiton

Research and Development Clinical Development Status (Major Changes since January 31, 2023) DSP-2342 U.S.: Started Phase 1 study (Proposed indication: To be determined) SEP-378608 U.S.: Discontinued development for bipolar disorder (Phase 1 study) Vibegron China: Started Phase 3 study (Overactive bladder) SP-101 U.S.: Started Phase 1 study (Proposed indication: cystic fibrosis) URO-902 U.S.: Discontinued in-house development for overactive bladder (OAB) (Phase 2 study), out-licensing under consideration Decided to discontinue development of DSP-0509, which was under consideration for development strategy Sumitomo Pharma © Sumitomo Pharma Co., Ltd. All Rights Reserved. 17

View entire presentation